Studies
Enrolling
All Studies
Expand your treatment options and enhance your practice by integrating clinical trials. Gain access to a diverse portfolio of studies, sourced from over 20 industry sponsors, and broaden the care you can offer your community. Our tailored approach to trial matching ensures your patients are connected with studies that meet their specific needs, allowing them to explore the latest advancements in care and discover how clinical trials can directly benefit their health journey. Find available trials nearby and empower your patients with access to cutting-edge treatments.
Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this trial is to evaluate whether home use of the myAirvo 3 device (High Flow Nasal Therapy, HFNT) improves outcomes for patients with moderate to very severe COPD compared to usual medical care. Specifically, it aims to determine if HFNT can delay or reduce exacerbations, hospitalizations, and mortality, while also improving quality of life.
Moderate to Severe Asthma
The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function.
Cachexia, Metastatic Colorectal Cancer
This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 100 patients with newly diagnosed metastatic colorectal cancer. This study will evaluate different doses of B07 on weight, body composition and BMI in patients with sub-optimal BMIs (18 to ≤ 29 kg/m2). Treatment will begin on the same day as the start of cancer chemotherapy and continue during the first 28 days of cytotoxic therapy with a goal of preserving muscle and fat mass, relative to placebo control.
Non-small Cell Lung Cancer – DESTINY-Lung06
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS <50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.
Chronic Lymphocytic Leukemia
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants may or may not have already had treatment for their cancer. Participation could last up to six years.
